RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare blood cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new tablet, XNW5004, against another drug (Chidamide) in people with a rare blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 120 adults aged 18-70 will participate. The main goal is to see if XNW5004 c…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 26, 2026 05:10 UTC
-
Promising drug cocktail targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests a combination of three drugs (anti-PD-1 antibody, lenalidomide, and azacitidine) in people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve survival. About…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug combo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests two experimental drugs, SHR-0302 and SHR-2554, in about 25 people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. The goal is to see if the combination can shrink or control the cancer. Participan…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 18, 2026 12:08 UTC